Phase III SELECT-PsA 1 study of Rinvoq shows positive top-line results in psoriatic arthritis.- AbbVie
Related news and insights
AbbVie announced that it has submitted applications seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for Skyrizi (risankizumab, 150 mg) to the European Medicines Agency (EMA) for the treatment of adults with active psoriatic arthritis.
AbbVie announced that the New England Journal of Medicine has published 24-week results from the Phase III SELECT-PsA 1 trial evaluating Rinvoq (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).
AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic arthritis.